Black Diamond Therapeutics Inc
$ 2.09
-0.48%
04 Jun - close price
- Market Cap 124,918,000 USD
- Current Price $ 2.09
- High / Low $ 2.21 / 2.07
- Stock P/E N/A
- Book Value 1.82
- EPS -0.77
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.19 %
- ROE -0.35 %
- 52 Week High 4.94
- 52 Week Low 1.93
About
Black Diamond Therapeutics, Inc., a biotechnology company, discovers and develops small molecule tumor agnostic therapies. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$9.86
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-16 | 2025-11-06 | 2025-08-07 | 2025-05-12 | 2025-03-06 | 2024-11-05 | 2024-08-06 | 2024-05-09 | 2024-03-12 | 2023-11-06 | 2023-08-11 |
| Reported EPS | -0.16 | -0.1361 | -0.15 | -0.19 | 0.98 | -0.28 | -0.2753 | -0.36 | -0.35 | -0.34 | -0.45 | -0.52 |
| Estimated EPS | -0.0294 | -0.1746 | -0.235 | -0.2467 | -0.255 | -0.3117 | -0.37 | -0.39 | -0.43 | -0.47 | -0.49 | -0.54 |
| Surprise | -0.1306 | 0.0385 | 0.085 | 0.0567 | 1.235 | 0.0317 | 0.0947 | 0.03 | 0.08 | 0.13 | 0.04 | 0.02 |
| Surprise Percentage | -444.2177% | 22.0504% | 36.1702% | 22.9834% | 484.3137% | 10.17% | 25.5946% | 7.6923% | 18.6047% | 27.6596% | 8.1633% | 3.7037% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BDTX
2026-06-02 19:37:36
Wedbush has reiterated its Buy rating for Black Diamond Therapeutics (BDTX.US), maintaining a target price of $14. This indicates the firm's continued confidence in the company's financial performance and future prospects.
2026-05-27 15:09:02
The article discusses Black Diamond Therapeutics' (BDTX) silevertinib, a fourth-generation EGFR inhibitor for non-small cell lung cancer, highlighting new Phase II data from May 2026. Key updates reveal systemic activity with a 60% objective response rate, promising central nervous system outcomes including an 86% CNS objective response rate, and an optimized dosing strategy of 150 mg once daily. Investors are advised to track upcoming clinical readouts, regulatory discussions, and potential business development as the company moves towards pivotal development and expands into glioblastoma.
2026-05-27 15:09:02
Black Diamond Therapeutics (BDTX) reported a Q1 earnings beat with a narrower loss of $0.16 per share, and management projects its $118.3 million cash reserve will fund operations into H2 2028. The company's future hinges on the clinical success of its sole wholly-owned asset, silevertinib, particularly in non-small cell lung cancer and glioblastoma, with an upcoming FDA meeting in 2026 for pivotal development discussions. Competition from companies like AstraZeneca and Johnson & Johnson in the EGFR NSCLC space intensifies the need for silevertinib to demonstrate clear differentiation and durability.
2026-05-27 09:37:36
Black Diamond Therapeutics (BDTX) delivered a Q1 earnings beat, with its stock heavily influenced by the clinical progress of silevertinib. The company has reduced operating expenses significantly and has sufficient cash to fund operations into the second half of 2028, supporting its focus on clinical and regulatory milestones. However, the company faces concentration risk with silevertinib as its sole clinical asset and significant competition in the EGFR NSCLC market.
2026-05-26 15:39:26
Black Diamond Therapeutics (BDTX) stock rose on Tuesday after the company reported encouraging Phase 2 data for silevertinib in non-small cell lung cancer, with findings to be presented at ASCO. The company also reported a narrower Q1 loss than estimated, and maintained cash solvency into late 2028. Analysts have a positive outlook on the stock, with an average "Buy" rating and price targets up to $14.00.
2026-05-25 15:39:16
Black Diamond Therapeutics (BDTX) shares dropped by 35.8% after reporting mixed Phase II data for its lead candidate, silevertinib, in first-line non-small cell lung cancer (NSCLC) patients with EGFR non-classical mutations. While the study showed promising efficacy, including a preliminary median progression-free survival of 15.2 months and strong central nervous system activity, investors expressed concerns regarding the early nature of the data, the small patient count, dose-related safety, and the lack of a clear pivotal path. The company plans to meet with the FDA later in 2026 to discuss development plans.
